Pfizer Stock Price Today: PFE Slips as mRNA Vaccine Worry Eases, Eczema Data Offers Fresh Catalyst
Pfizer slipped roughly 0.4% to $27.05 midday Wednesday in New York. Investors reacted after the Washington Post said U.S. vaccine advisers scrapped plans to scrutinize mRNA COVID vaccines, removing a potential regulatory obstacle for the company’s vaccine segment.
